Takeda Highlights Late-Stage Oncology Pipeline Progress and Solid Tumor Portfolio Research, Led by Late-Breaking Phase 3 ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep 22, 2026-- Takeda ( TSE:4502/NYSE:TAK ) announced that new data from its oncology pipeline and portfolio will be presented at the European Society for Medical Oncology (ESMO) Congress, taking …